

From: [Walker, Keri \(NIH/OD\) \[C\]](#)
To: cramer@umn.edu
Cc: [Gibbens, Robert - APHIS](#) (b) (6)
Subject: OLAW Case A3456-9A
Date: Tuesday, October 13, 2020 9:52:12 AM
Attachments: [Cramer UMN 3456-9A.pdf](#)

Dear Dr. Cramer,

Attached please find Dr. Morse's final response to OLAW Case A3456-9A.

If you have any questions, feel free to contact us by phone or by e-mail.

Best Regards,
Keri

*Keri Walker
Program Analyst (Contractor)
Division of Compliance Oversight
Office of Laboratory Animal Welfare
National Institutes of Health
6700B Rockledge Dr., Suite 2500
Bethesda, MD 20892
301-435-2390
keri.walker@nih.gov*



DEPARTMENT OF HEALTH & HUMAN SERVICES

PUBLIC HEALTH SERVICE
NATIONAL INSTITUTES OF HEALTH

FOR US POSTAL SERVICE DELIVERY:

Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500, MSC 6910
Bethesda, Maryland 20892-6910
Home Page: <http://grants.nih.gov/grants/olaw/olaw.htm>

FOR EXPRESS MAIL:

Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500
Bethesda, Maryland 20817
Telephone: (301) 496-7163
Facsimile: (301) 480-3387

October 13, 2020

Re : Animal Welfare Assurance
#A3456-01 [OLAW Case 9A]
UMN IACUC #37591A

Dr. Christopher Cramer
Vice President for Research
Institutional Official
University of Minnesota
(b) (4) Johnston Hall - 101 Pleasant St., SE
Minneapolis, MN 55455

Dear Dr. Cramer,

The Office of Laboratory Animal Welfare (OLAW) acknowledges receipt of your September 21, 2020 letter reporting a noncompliance with the PHS Policy on the Humane Care and Use of Laboratory Animals at the University of Minnesota (IACUC #37591A). According to the information provided it is understood that although a pig received SR buprenorphine and Carprofen pre- and post-operatively on January 24, 2020, according to the protocol, the animal did not receive lidocaine/bupivacaine at the laparotomy site prior to closure as part of the implant surgery. This deviation in protocol occurred in one animal. The activity involved was supported by PHS funds.

Corrective and preventive actions included the PI confirming that if more work is performed on this study, lidocaine/bupivacaine will be given at the site of surgery prior to closure as is outlined in the approved protocol.

OLAW believes that the corrective and preventive measures put in place by the University of Minnesota are consistent with the provisions of the PHS Policy on Humane Care and Use of Laboratory Animals for institutional self-monitoring and self-reporting. We appreciate being informed of this matter and find no cause for further action by this office.

Sincerely,

Brent C. Morse, DVM
Director
Division of Compliance Oversight
Office of Laboratory Animal Welfare

cc: IACUC contact
Dr. Robert M. Gibbens, USDA, APHIS, AC

From: [Gibbens, Robert - APHIS](#)
To: [Martha - APHIS Keller \(Martha.Keller@usda.gov\)](#); [Hovancsak, Catherine F - APHIS](#)
Subject: FW: OLAW Case A3456-9A
Date: Tuesday, October 13, 2020 9:54:00 AM
Attachments: [Cramer UMN 3456-9A.pdf](#)

From: Walker, Keri (NIH/OD) [C] <keri.walker@nih.gov>
Sent: Tuesday, October 13, 2020 7:51 AM
To: cramer@umn.edu
Cc: Gibbens, Robert - APHIS <robert.m.gibbens@usda.gov>; (b) (6)
Subject: OLAW Case A3456-9A

Dear Dr. Cramer,

Attached please find Dr. Morse's final response to OLAW Case A3456-9A.

If you have any questions, feel free to contact us by phone or by e-mail.

Best Regards,
Keri

*Keri Walker
Program Analyst (Contractor)
Division of Compliance Oversight
Office of Laboratory Animal Welfare
National Institutes of Health
6700B Rockledge Dr., Suite 2500
Bethesda, MD 20892
301-435-2390
keri.walker@nih.gov*



DEPARTMENT OF HEALTH & HUMAN SERVICES

PUBLIC HEALTH SERVICE
NATIONAL INSTITUTES OF HEALTH

FOR US POSTAL SERVICE DELIVERY:

Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500, MSC 6910
Bethesda, Maryland 20892-6910
Home Page: <http://grants.nih.gov/grants/olaw/olaw.htm>

FOR EXPRESS MAIL:

Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500
Bethesda, Maryland 20817
Telephone: (301) 496-7163
Facsimile: (301) 480-3387

October 13, 2020

Re : Animal Welfare Assurance
#A3456-01 [OLAW Case 9A]
UMN IACUC #37591A

Dr. Christopher Cramer
Vice President for Research
Institutional Official
University of Minnesota
(b) (4) Johnston Hall - 101 Pleasant St., SE
Minneapolis, MN 55455

Dear Dr. Cramer,

The Office of Laboratory Animal Welfare (OLAW) acknowledges receipt of your September 21, 2020 letter reporting a noncompliance with the PHS Policy on the Humane Care and Use of Laboratory Animals at the University of Minnesota (IACUC #37591A). According to the information provided it is understood that although a pig received SR buprenorphine and Carprofen pre- and post-operatively on January 24, 2020, according to the protocol, the animal did not receive lidocaine/bupivacaine at the laparotomy site prior to closure as part of the implant surgery. This deviation in protocol occurred in one animal. The activity involved was supported by PHS funds.

Corrective and preventive actions included the PI confirming that if more work is performed on this study, lidocaine/bupivacaine will be given at the site of surgery prior to closure as is outlined in the approved protocol.

OLAW believes that the corrective and preventive measures put in place by the University of Minnesota are consistent with the provisions of the PHS Policy on Humane Care and Use of Laboratory Animals for institutional self-monitoring and self-reporting. We appreciate being informed of this matter and find no cause for further action by this office.

Sincerely,

Brent C. Morse, DVM
Director
Division of Compliance Oversight
Office of Laboratory Animal Welfare

cc: IACUC contact
Dr. Robert M. Gibbens, USDA, APHIS, AC

From: [Hovancsak, Catherine F - APHIS](#)
To: [Gibbens, Robert - APHIS](#); [Keller, Martha - APHIS](#)
Subject: RE: OLAW Case A3456-9A
Date: Tuesday, October 13, 2020 9:56:38 AM

Got it -

Thanks,

Cathy

From: Gibbens, Robert - APHIS
Sent: Tuesday, October 13, 2020 8:55 AM
To: Keller, Martha - APHIS <Martha.Keller@usda.gov>; Hovancsak, Catherine F - APHIS <cathy.f.hovancsak@usda.gov>
Subject: FW: OLAW Case A3456-9A

From: Walker, Keri (NIH/OD) [C] <keri.walker@nih.gov>
Sent: Tuesday, October 13, 2020 7:51 AM
To: cramer@umn.edu
Cc: Gibbens, Robert - APHIS <robert.m.gibbens@usda.gov>; (b) (6)
Subject: OLAW Case A3456-9A

Dear Dr. Cramer,

Attached please find Dr. Morse's final response to OLAW Case A3456-9A.

If you have any questions, feel free to contact us by phone or by e-mail.

Best Regards,
Keri

*Keri Walker
Program Analyst (Contractor)
Division of Compliance Oversight
Office of Laboratory Animal Welfare
National Institutes of Health
6700B Rockledge Dr., Suite 2500
Bethesda, MD 20892
301-435-2390
keri.walker@nih.gov*